Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis

Experimental & Molecular Medicine 2022³â 54±Ç 12È£ p.2107 ~ 2117
À¯Á¤, ±è°í¿î, ÀüÀ¯Çö, ±èÁöÀ±, ÀÌ»ó¿ì, ±Ç¼ÒÈñ,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯Á¤ ( Yoo Jung ) 
Yonsei University College of Pharmacy

±è°í¿î ( Kim Go-Woon ) 
Yonsei University College of Pharmacy
ÀüÀ¯Çö ( Jeon Yu-Hyun ) 
Yonsei University College of Pharmacy
±èÁöÀ± ( Kim Ji-Yoon ) 
Yonsei University College of Pharmacy
ÀÌ»ó¿ì ( Lee Sang-Wu ) 
Yonsei University College of Pharmacy
±Ç¼ÒÈñ ( Kwon So-Hee ) 
Yonsei University College of Pharmacy

Abstract


Distinct epigenetic modifiers ensure coordinated control over genes that govern a myriad of cellular processes. Growing evidence shows that dynamic regulation of histone methylation is critical for almost all stages of development. Notably, the KDM5 subfamily of histone lysine-specific demethylases plays essential roles in the proper development and differentiation of tissues, and aberrant regulation of KDM5 proteins during development can lead to chronic developmental defects and even cancer. In this review, we adopt a unique perspective regarding the context-dependent roles of KDM5A and KDM5B in development and tumorigenesis. It is well known that these two proteins show a high degree of sequence homology, with overlapping functions. However, we provide deeper insights into their substrate specificity and distinctive function in gene regulation that at times divert from each other. We also highlight both the possibility of targeting KDM5A and KDM5B to improve cancer treatment and the limitations that must be overcome to increase the efficacy of current drugs.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

SCI(E)
MEDLINE
KCI
KoreaMed
KAMS